• GPR107 Deficiency Intensifies Diabetic Nephropathy via AT1R

  2026-07-20

  Xu et al. uncover a mechanistic link between GPR107 deficiency and aggravated diabetic nephropathy, showing that loss of GPR107 enhances angiotensin II receptor activity and collagen IV accumulation in podocytes. These findings highlight new avenues for targeting extracellular matrix balance and angiotensin II signaling in diabetic kidney disease.

• DiscoveryProbe Bioactive Compound Library Plus: Unveiling Li

  2026-07-19

  Explore how the DiscoveryProbe Bioactive Compound Library Plus revolutionizes ligand functionality analysis in intricate biological pathways. This in-depth article reveals practical insights for assay optimization, referencing recent advances in ligand screening.

• Strategic Advances in Alcian Blue & Nuclear Fast Red Stainin

  2026-07-18

  This article delivers a thought-leadership perspective on the mechanistic and strategic significance of the Alcian Blue & Nuclear Fast Red Staining Kit, pH2.5 for translational researchers. Bridging molecular specificity, workflow optimization, and the nuanced needs of small tissue biopsies and stem cell differentiation assays, it integrates recent peer-reviewed evidence and advanced protocol recommendations to empower research scalability and interpretative clarity.

• Baricitinib (LY3009104): Unraveling JAK1/2-IL-6 Crosstalk in

  2026-07-17

  Explore Baricitinib (LY3009104) as a precision tool for dissecting JAK1/2-driven IL-6 and STAT3 signaling in complex immune environments. This article offers new practical insights for immunology assay design, grounded in recent spatial proteomics of cell-cell communication.

• Palonosetron Hydrochloride in Chemotherapy-Induced Nausea: E

  2026-07-17

  This review analyzes the pharmacological innovation and clinical impact of palonosetron hydrochloride as presented by Ruhlmann and Herrstedt, highlighting its unique efficacy in both acute and delayed chemotherapy-induced nausea and vomiting. The work underscores how palonosetron’s allosteric 5-HT3 receptor binding differentiates it from earlier antiemetics, with implications for protocol design and corticosteroid adjunct use.

• 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine i

  2026-07-16

  5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine uniquely enables high-fidelity studies of α2-adrenergic receptor signaling, immune rejection modulation, and post-surgery osteosarcoma recurrence models. Its exceptional purity and DMSO solubility streamline advanced experimental workflows, supporting reproducible translational research.

• Microfluidized Dextran Microgels Enable Targeted Oral Colon

  2026-07-16

  This study introduces a dual-targeted microgel system for oral delivery of cisplatin and SPION lipid nanoparticles, enhancing site-specific accumulation and therapeutic efficacy in colon cancer models. The approach addresses key barriers in oral chemotherapeutic delivery and demonstrates significant tumor inhibition with minimized systemic exposure.

• N3-kethoxal: Transforming RNA and DNA Structure Mapping

  2026-07-15

  This thought-leadership article explores how N3-kethoxal, an azide-functionalized nucleic acid probe from APExBIO, is revolutionizing RNA secondary structure probing and genomic mapping of accessible DNA. Drawing from recent advances such as the CasKAS assay and multiomic workflows, the piece delivers mechanistic insight and strategic guidance for translational researchers. Key protocol parameters, competitive differentiation, and a forward-looking outlook round out this comprehensive perspective.

• Tolazoline as an α2-Adrenergic Receptor Antagonist: Applied

  2026-07-15

  Tolazoline stands out for its dual modulation of α2-adrenergic receptors and ATP-sensitive potassium channels, making it an indispensable tool in airway smooth muscle and islet function research. This article delivers actionable protocols, troubleshooting strategies, and data-driven insights to maximize reproducibility and mechanistic clarity with APExBIO’s high-purity Tolazoline.

• Galectin-1 Impairs Autophagy and Drives Hepatic Steatosis vi

  2026-07-14

  This study identifies galectin-1 as a direct inhibitor of hepatic autophagy through its interaction with FIP200, leading to exacerbation of non-alcoholic fatty liver disease (NAFLD) features such as steatosis and insulin resistance. The findings clarify a mechanistic link between autophagy dysfunction and metabolic liver disease, highlighting a novel therapeutic target.

• Selective β1 Blockade Spares Hematopoietic Regeneration Afte

  2026-07-14

  This study demonstrates that nonselective β-adrenergic blockers, but not β1-selective agents like Metoprolol Tartrate, impair hematopoietic regeneration following hematopoietic cell transplantation (HCT) in both mice and humans. The findings inform cardiovascular and transplantation research protocols, emphasizing the importance of β-adrenergic receptor selectivity to avoid unintended effects on bone marrow recovery.

• Protoporphyrin IX: Photodynamic Compound Workflows in HCC

  2026-07-13

  Leverage Protoporphyrin IX's dual role as a heme biosynthetic intermediate and a photodynamic compound to drive innovation in cancer research. This guide translates cutting-edge findings into actionable workflows, troubleshooting strategies, and advanced applications, empowering experimentalists to precisely model ferroptosis and tumor biology.

• Cyanine 3 Tyramide: Beyond Amplification in Neurobiological

  2026-07-13

  Explore how Cyanine 3 Tyramide empowers fluorescent dye-based signal amplification for biomedical research, with a special focus on assay optimization and translational neurobiology. This article delivers a new perspective on technical rigor and experimental design.

• Multi-Omics Unveils ARID1A-Dependent Resistance in Melanoma

  2026-07-12

  This study employs integrative multi-omics to map early and stable resistance mechanisms to BRAF/MAPK inhibition in melanoma, focusing on the role of ARID1A loss. The findings reveal complex signaling rewiring and immune evasion that define resistance, highlighting actionable nodes for future research and therapeutic targeting.

• EZ Cap™ Cas9 mRNA (5-moUTP): Optimizing CRISPR Neurodegenera

  2026-07-10

  EZ Cap™ Cas9 mRNA (5-moUTP) empowers researchers to perform high-efficiency, low-immunogenicity gene editing in sensitive CNS models. This article delivers actionable protocol guidance, troubleshooting strategies, and workflow enhancements rooted in the latest zebrafish neurodegeneration research.

454 records 11/31 page Previous Next First page 上5页 1112131415 下5页 Last page